These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 8471593)

  • 1. Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta.
    Witt PL; Storer BE; Bryan GT; Brown RR; Flashner M; Larocca AT; Colby CB; Borden EC
    J Immunother Emphasis Tumor Immunol; 1993 Apr; 13(3):191-200. PubMed ID: 8471593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
    Goldstein D; Sielaff KM; Storer BE; Brown RR; Datta SP; Witt PL; Teitelbaum AP; Smalley RV; Borden EC
    J Natl Cancer Inst; 1989 Jul; 81(14):1061-8. PubMed ID: 2472488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
    Schiller JH; Storer B; Witt PL; Nelson B; Brown RR; Horisberger M; Grossberg S; Borden EC
    Cancer Res; 1990 Aug; 50(15):4588-94. PubMed ID: 2114942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of 2'-5'-oligoadenylate synthetase in serum and peripheral blood mononuclear cells before and after subcutaneous application of recombinant interferon beta and gamma.
    Bruchelt G; Fierlbeck G; Schiebel U; Bogenschütz O; Rassner G; Niethammer D
    Eur J Clin Chem Clin Biochem; 1992 Sep; 30(9):521-8. PubMed ID: 1457613
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
    Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
    Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
    Schiller JH; Storer B; Paulnock DM; Brown RR; Datta SP; Witt PL; Borden EC
    J Clin Invest; 1990 Oct; 86(4):1211-21. PubMed ID: 2120284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers.
    Salmon P; Le Cotonnec JY; Galazka A; Abdul-Ahad A; Darragh A
    J Interferon Cytokine Res; 1996 Oct; 16(10):759-64. PubMed ID: 8910759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel PEGylated interferon beta-1a for multiple sclerosis: safety, pharmacology, and biology.
    Hu X; Miller L; Richman S; Hitchman S; Glick G; Liu S; Zhu Y; Crossman M; Nestorov I; Gronke RS; Baker DP; Rogge M; Subramanyam M; Davar G
    J Clin Pharmacol; 2012 Jun; 52(6):798-808. PubMed ID: 21680782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absence of biological effects of orally administered interferon-beta ser.
    Witt PL; Goldstein D; Storer BE; Grossberg SE; Flashner M; Colby CB; Borden EC
    J Interferon Res; 1992 Dec; 12(6):411-3. PubMed ID: 1289408
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacodynamic comparison of single doses of IFN-beta1a and IFN-beta1b in healthy volunteers.
    Stürzebecher S; Maibauer R; Heuner A; Beckmann K; Aufdembrinke B
    J Interferon Cytokine Res; 1999 Nov; 19(11):1257-64. PubMed ID: 10574618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and clinical effects of interferon-beta ser at two doses.
    Borden EC; Rinehart JJ; Storer BE; Trump DL; Paulnock DM; Teitelbaum AP
    J Interferon Res; 1990 Dec; 10(6):559-70. PubMed ID: 2086672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers.
    Rothuizen LE; Buclin T; Spertini F; Trinchard I; Munafo A; Buchwalder PA; Ythier A; Biollaz J
    J Neuroimmunol; 1999 Sep; 99(1):131-41. PubMed ID: 10496186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
    Witt PL; Spear GT; Lindstrom MJ; Kessler HA; Borden EC; Phair J; Landay AL
    AIDS; 1991 Mar; 5(3):289-93. PubMed ID: 2059368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-beta given intravenously.
    Liberati AM; Garofani P; De Angelis V; Di Clemente F; Horisberger M; Cecchini M; Betti AR; Palmisano L; Astolfi S; Nastari A
    J Interferon Res; 1994 Apr; 14(2):61-9. PubMed ID: 8077767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased interferon binding capacity of peripheral blood mononuclear cells during interferon treatment of chronic hepatitis B with special reference to (2'-5') oligoadenylate synthetase activity.
    Shindo M; Iwata A; Okuno T; Matsumoto M; Takeda M; Arai K; Sokawa Y
    Gastroenterol Jpn; 1989 Dec; 24(6):670-5. PubMed ID: 2481600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of 2',5'-oligoadenylate synthetase and B-2 microglobulin in cancer patients treated with partially pure gamma interferon: dependence of biological effect on administration route.
    Rosenblum MG; Riso A; Gutterman JU
    Cancer Chemother Pharmacol; 1986; 16(3):273-6. PubMed ID: 3084109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma.
    Paulnock DM; Havlin KA; Storer BM; Spear GT; Sielaff KM; Borden EC
    J Interferon Res; 1989 Aug; 9(4):457-73. PubMed ID: 2502586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
    Witt PL; Ritch PS; Reding D; McAuliffe TL; Westrick L; Grossberg SE; Borden EC
    Cancer Res; 1993 Nov; 53(21):5176-80. PubMed ID: 8221654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of PEGylated IFN-beta 1a following subcutaneous administration in monkeys.
    Mager DE; Neuteboom B; Jusko WJ
    Pharm Res; 2005 Jan; 22(1):58-61. PubMed ID: 15771230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics of recombinant IFN-beta during long-term treatment of malignant melanoma.
    Fierlbeck G; Ulmer A; Schreiner T; Stroebel W; Schiebel U; Brzoska J
    J Interferon Cytokine Res; 1996 Oct; 16(10):777-81. PubMed ID: 8910762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.